Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone801-994-7383
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
Next Earnings Date3/11/2019 (Estimated)
OptionableOptionable
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc (NASDAQ:LPCN) announced its quarterly earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.12. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
4 equities research analysts have issued 12-month target prices for Lipocine's shares. Their forecasts range from $1.50 to $10.00. On average, they anticipate Lipocine's stock price to reach $4.8333 in the next twelve months. This suggests a possible upside of 184.3% from the stock's current price. View Analyst Price Targets for Lipocine.
What is the consensus analysts' recommendation for Lipocine?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lipocine.
Has Lipocine been receiving favorable news coverage?
News articles about LPCN stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lipocine earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include BELLUS Health (BLUSF), Aquestive Therapeutics (AQST), Millendo Therapeutics (MLND), Bellicum Pharmaceuticals (BLCM), Humanigen (HGEN), Cue Biopharma (CUE), Eton Pharmaceuticals (ETON), BioXcel Therapeutics (BTAI), Correvio Pharma (CORV), Sierra Oncology (SRRA), Northwest Biotherapeutics (NWBO), Unum Therapeutics (UMRX), Sol Gel Technologies (SLGL), DURECT (DRRX) and Fortress Biotech (FBIO).
What other stocks do shareholders of Lipocine own?
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
- Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
- Logan Morse, VP of Sales, Marketing & Operations (Age 49)
- Nachiappan Chidambaram, VP of Product Devel. (Age 50)
- Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)
Who are Lipocine's major shareholders?
Lipocine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.09%). Company insiders that own Lipocine stock include Gregory Brooks Bass, Jeffrey Arvin Fink, Mahesh V Patel, Morgan R Brown and Stephen A Hill. View Institutional Ownership Trends for Lipocine.
Which institutional investors are selling Lipocine stock?
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $1.70.
How big of a company is Lipocine?
Lipocine has a market capitalization of $36.49 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.
What is Lipocine's official website?
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
